Artenga’s microbubble drug conjugates (MDC) are used with focused ultrasound (FUS) as a key enabler for:

  • Safe, non-invasive, targeted blood brain barrier drug delivery
  • Boosting immunotherapy efficacy without added toxicity

Our Sunnybrook collaborators did first in human FUS and (non-drug loaded) microbubble BBB opening for glioblastoma, Alzheimer’s, breast cancer brain mets, and ALS.

Artenga’s differentiation:

  • Higher dose delivered with greater perfusion
  • Liver clearance of unused drug to mitigate systemic effects
  • AAV gene therapy MDC and technology to prevent peripheral dosing
Artenga Inc. logo



Event details

Date: September 14 - 16, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


16 in total